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Introduction
Colorectal cancer (CRC) is the fourth most common 
cancer in the world. Colorectal cancer is one of the most 
common cancers in the world, accounting for nearly 10 
percent of new cases of all cancer (Gou et al., 2014). 
Each year 1.5 million people worldwide are diagnosed 
with CRC. In America around 60,000 deaths due to CRC 
happens. Men and women are almost equally affected, 
and its prevalence increases gradually from age 40 to 50 
years. In Iran the incidence of this cancer is on the rise 
and in now CRC is the fourth most common cancer among 
men (5%) and women (5.5%), respectively. Surprisingly, 
in Iran prevalence of CRC in men under 50 years old is 
remarkable. 
Due to the slow development of CRC and the ability to 
treat at the early stages, screening for CRC can reduce the 
incidence of death and mortality in this disease. Therefore, 
a noninvasive biomarker for early detection of the disease 
can be useful (Kanojia et al., 2011).
Cancer-Testis antigens (CTAs) are molecules 
characterized by expression restricted to normal testis 
tissue but aberrant expression in a variety of cancer 
types (John et al., 2013). Although the biological role 
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of CTA are not fully understood, but their association 
with cell proliferation, migration and invasion are well 
documented (Agarwal et al., 2013b). CT antigens have 
been proposed to play pivotal role in various malignant 
properties of cancer cells (Sinha et al., 2013). Recently, 
some investigations have been carried out using RT-PCR 
and statistical analysis to reveal the correlation of some 
CTA genes expression and clinical risk factors with 
malignancy in CRCs (Almanzar et al., 2009; Chen et al., 
2010). In theory CTA can be detected only in cancer cells 
and not normal cells. Therefore, if a CTA proven that is 
detected in cancer cells eg. Breast cancer cells, it may have 
the potential to be considered as diagnostic biomarker for 
breast cancer. However, a specific CTA can be expressed 
in an eg. Breast cancer tissues but not in colorectal tissues. 
Thus some of the CTA are cancer specific.
AKAP4 is a member of CTA family encoded by 
X-chromosome (Saini et al., 2013a). AKAP4 is a 
member of the A-kinase anchor proteins which bind the 
protein kinase A (PKA) regulatory subunit and functions 
to anchor PKA to specific cellular locations. Previous 
studies demonstrated that AKAP4 plays a role in tumor 
development and progression, including esophageal 
cancer, ovarian cancer, breast cancer and lung cancer 
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(Han et al., 2017). SPAG9 is a cytoplasmic enzyme 
and initially found as a scaffolding protein that bring 
MAPKs and their target transcription factors (Wang et 
al., 2013). SPAG9 is a member of the CTA family that 
is highly expressed in many types of cancers such as in 
88% of breast cancer, 82% of cervical cancer, 74% of 
colorectal cancer, and 60% of astrocytoma that causes 
a strong immune response (Ren et al., 2016; Yan et 
al., 2016). Studies of SPAG9 suggest that it promotes 
proliferation and invasion (Ren et al., 2016). CTAG1B, 
the gene for NY-ESO-1, is located at Xq28 and codes for 
an intracellular, 18-kDa protein(Hemminger et al., 2013). 
The function of NY-ESO-1 is unknown; however, it has 
been postulated that cancer-testis antigens in general are 
involved in germ cell self-renewal or differentiation, 
conferring qualities such as immortality, self-renewal, 
migratory ability, and capacity to transform to cancer cells 
upon expression (Hemminger et al., 2013). The CT antigen 
NY-ESO-1/CTAG1/CT6 was first identified by SEREX 
in esophageal squamous cell carcinoma (Pagotto et al., 
2013). NY-ESO-1 exhibits a relatively unique architecture, 
with a Pcc-1 domain in the C-terminus (89-164 aa) 
homologous to a yeast transcription factor involved in 
cell cycle progression and polarized growth(Pagotto et 
al., 2013). Its aberrant expression has been observed in 
a variety of neoplasms, including esophageal carcinoma, 
hepatocellular carcinoma, melanoma, and synovial 
sarcoma(Lai et al., 2012).
In the current study, we aimed to investigate the 
expression of these  three CTA genes in Iranian CRC 
patients and their possible associations with some clinical 
risk The selection of these three CTA genes was based on 
two key reasons: (1) their presence in colorectal cancer 
tissue or cell lines and (2) their association with tumor 




Sixty two newly diagnosed cases with locally advanced 
colorectal cancer admitted to Rasoul Akram Hospital in 
Tehran, and willing to collaborate were enrolled in this 
study during the years 2008 to 2013. Only sporadic CRC 
patients were enrolled in this study.  The samples were 
collected during surgery. Patients had received no other 
treatment such as chemotherapy before surgery.
The project was approved by the local ethics 
committee of Rasoul Akram Hospital and written informed 
consent was obtained from each case. Clinicopathological 
characteristics contained demographic variables (age, 
gender), tumor size, tumor location (colon and rectum), 
and pathological status classified according to the TNM 
system. During surgery and before any chemotherapy 
treatments, fresh tissue specimens and paired adjacent 
normal tissues were collected by the clinicians in separated 
sterile tubes. Tissue samples were frozen and stored at 
−70 oC. 
RNA Extraction and cDNA Synthesis
Total RNA extraction was performed from 50–100 mg 
of each sample with the TriPure Isolation Reagent (Roche 
Applied Sciences, Germany). For cDNA synthesis, 3 µg 
of total RNA from each sample was used to synthesize 
fist-strand cDNA according to the manufacturer protocol 
(Fermentas, Germany).
Reverse Transcriptase-Polymerase Chain Reaction 
To evaluate the expression of individual CTA genes, all 
reactions were carried out in a peqSTAR 96 Universal 
Thermal Cycler. The PCR mixture included 1 µM primer, 
200 µM of each dNTP (KBC), reaction buffer 1x with 
1.5 mMolar Mgcl2, and 1 unit Taq polymerase (5 U/µL, 
KBC). The PCR analysis was performed on selected genes 
using the primers and the conditions shown in Table 1. 
Amplified segments were analyzed by electrophoresis on 
a 2.5% agarose gel, stained with ethidium bromide, and 
observed under E box vx2 ultraviolet light system. 
Statistical Analysis
All the data were tabulated, and the statistical analysis 
was performed using the SPSS software V22.0 (SPSS, 
IBM Corp.: Armonk, NY). Association of the frequency 
of CTA genes expression and clinicopathological markers 
was analyzed using Fisher’s exact test for a two-by-two 
contingency table or by the Pearson χ2 test. 
In all statistical analyses, a value less than 0.05 
was considered to be statistically significant. All of the 
clinicopathological variables assessed in this study were 
categorized hence to create the two-by-two contingency 
table, we divided each of them into two groups according 
to their calculated means (Table 2 and 3). Finally, the 
coexpression of the CTA genes as well as the association 




Sample tissues were collected from 62 CRC patients 
including tumoral and adjacent normal tissues (27 male, 
34 female; F/M = 1.2/1) and 10 colon tissues from healthy 
controls from Rasoul Akram Hospital in Tehran.
Result s of RT- PCR Amplification
CTA mRNA expression was investigated in 62 CRC 
cancer specimens and paired adjacent normal tissues and 
colon tissues of healthy controls by RT-PCR. None of these 
genes were expressed in normal mucosal tissues. SPAG9 
mRNA expression was found in 41 of 62 (66%) tumoral 
tissue specimens and AKAP4 SPAG9 mRNA expression 
was found in 27 of 62 (44%) tumoral tissue specimens 
irrespective of tumor stages. NY-ES0-1 mRNA expression 
was not observed in any tumoral tissue specimens. Positive 
RT-PCR results for each CTA gene studied, was shown 
in Figure 1. 
Correlation between CTA mRNA expression and 
clinicopathological markers
The relation between clinical risk factors and the 
expression frequency of the three CTA genes were 
examined (Table 2 and 3). Our results revealed that the 
expression of AKAP4 was significantly correlated with 
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Co-expression of CTA genes in CRC. At least one of the 
above CT genes was expressed in 40 patients (64%) of 
all 62 CRC patients
Among them, both of AKAP4 and SPAG9 genes were 
expressed in 14 patients (23%) and none of CT genes 
expressed in the other 8 patients (13%). The expression 
of AKAP4 was significantly associated with SPAG9 gene 
expression (p< 0.05).
Patients follow-up
Among the patients studied, 14 patients had recurrence, 
3 more patients had metastasis to liver, 4 patients passed 
away; one due to metastasis and 3 for non-cancerous 
reasons. The rest of the patients are alive and without 
metastasis (Table 4). 
Among patients with metastasis and relapse, AKAP4 
expression was observed in 21 and SPAG9 gene expression 
was observed in 26, and both genes were expressed in 14 
cases. In fact, the expression of the AKAP4 gene in about 
45% of patients and the expression of the SPAG9 gene in 
about 55% of patients and the expression of both genes in 
about 30% of the patients studied could be as a prognostic 
biomarker for the relapse or metastasis of CRC.
liver metastasis (M category) (< 0.05). The SPAG9 and 
AKAP4 expressions were revealed to be independent of 
tumor stages, tumor size, lymph node involvement, age 
and gender of the patients (p>0.05).
Genes Primers sequence (5’→ 3’) Denaturation Annealing Extension Cycle (no.)
AKAP4 TCCAGCTCAGAAGGCAACT 95 oC--- 30 s 59 oC---30 s 72oC---25 s 35
CGCCCTCTGTGTCTCCTAC
SPAG9 GCAGTAAACAGCGAAGTG 95 oC---30 s 64.2 oC---30 s 72 oC ---25 s 40
CTTTTGTAGCCGAATGAGT
CTAG1B CGACAACATACTGACTATCCG 94 oC---30s 58 oC---30 s 72 oC---45s 35
CCTCCAGCGACAAACAATC
Table 1. Primers and Condition of RT-PCR Analysis
SPAG9 expression 
percentage
Clinical Factor Number of cases - + P-
value
Gender Male (n=27) 26 74
Female (n=34) 28 62 0.412
Age (years) >50 (n=39) 31 69
≤50 (n=21) 38 62 0.579
T category (A) TX (n=2) 100 0
T1 (n=5) 20 80
T2 (n=14) 43 57 0.261
T3 (n=30) 33 67
T4 (n=9) 22 78
T category (B) TX & T1 & T2 (n= 21) 41 59
T3 & T4 (n=39) 32 68 0.577
Relapse + (n=43) 46 54
- (n=13) 33 67 0.51
N category (A) N0 (n=31) 39 61
N1 (n=22) 27 73 0.686
N2 (n=9) 33 67
N category (B) N0 (n=30) 40 60
N1 & N2 (n=31) 30 70 0.426
M category M0 (n=51) 31 69
M1 (n=11) 45 55 0.485
Tumor Size 
(centimeters) 
1.5-3 (n=22) 36 64
3.1-5.5 (n=19) 32 68 0.948
5.6-12 (n=20) 35 65
Stage Stage 0 (n=6) 33 67
Stage 1 (n=14) 36 64
Stage 2 (n=19) 47 53 0.504
Stage 3 (n=16) 25 75
Stage 4 (n=7) 14 86
p* < 0.05 significance association between gene expression and 
clinical risk factors ;T category, The rate of growth and progression of 
tumors in the intestinal wall layers based on the pathological division; 
M, Metastasis to other organs (M0: non metastatic, M: metastatic); 
N, Lymph node involvement (N0: no involvement); Tumor Size, 
The length of tumors in centimeters; Relapse, Tumor Recurrence (+: 
Recurrence, -: no Recurrence); Stage, Stage of cancer according to 
TNM classification System and pathological data.
Table 2. The Relation between the Percentages of the 
Positive Samples for SPAG9 Gene Expression and 
Clinicopathological Data at Diagnosis
Figure 1. The Result of RT-PCR Analysis of Positive 
mRNA Expression of CTAG1B (A, 261 bp), SPAG9 (B, 
141 bp), AKAP4 (C, 250 bp) Genes in Some Patients, 
M, Molecular marker; N, Negative control; +, Positive 
control (cDNA from testis).
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Discussion 
Colorectal cancer is the third most common cancer in 
the world, with nearly 1.4 million new cases diagnosed 
in 2012 (Ferlay et al., 2014). In Iran, CRC, is the most 
common fatal cancer (5000 new cases per year) (Kanojia 
et al., 2011). If the CRC diagnosed in early stages, 
before the lymph-vascular invasion, the survival will be 
increased. Therefore there is an urgent need to identify 
biomarkers in the early stages of CRC (Kanojia et al., 
2011). Over the last decades, tremendous studies about 
cancer molecular markers have been accomplished; 
however, only a few such markers have entered clinical 
practice. The lack of clinical prognostic markers clearly 
reflects limitations in prognostic studies. Although the 
function of CTA genes is still largely unknown partly due 
to their presence in multiple tumor types, their limited 
expression in normal tissue has made them ideal molecular 
markers for cancer prognosis and diagnosis (Odunsi et al., 
2007; Atanackovic et al., 2008). To improve the prognosis 
of CRC, the most significant considerations are the 
selection of patients at high risk for liver metastasis and 
subsequently the initiation of suitable adjuvant therapy. 
Adjuvant therapy in patients with CRC after curative 
resection has been reported to be useful for improving 
overall and disease-free survival (Watanabe et al., 2001; 
Cascinu et al., 2002).
The current study is the first to describe AKAP4, 
SPAG9 and NY-ESO-1 genes expression in Iranian CRC 
patients. 
Agarwal et al., (2013) study revealed that AKAP4 
gene and protein expression was detected in 86% of 
total patients with cervical cancer. AKAP 4 expression 
was significantly associated with early grades tumor 
specimens (P = 0.023). In addition, humoral response 
was detected in 53% of patients irrespective of stages, 
lymph node positivity, and grades (Agarwal et al., 2013a). 
Saini et al., (2013b) concluded that AKAP4 may be used 
as serum based diagnostic test for an early detection and 
diagnosis of breast cancer and may be a potential target for 
immunotherapeutic use. Chiriva -Internati et al., (2012) 
demonstrated the aberrant expression of AKAP-4 in PC 
(prostate cancer), which will potentially be developed as a 
biomarker in PC (Chiriva-Internati et al., 2012). Agarwal 
et al., (2013) results revealed that AKAP4 was expressed 
at both the mRNA and protein levels in 89% (34/38) of 
ovarian carcinoma tissue specimens but not in 21 matched 
adjacent non-cancerous tissues.
According to our data, a significant association 
between AKAP4 expression and liver metastasis was 
shown suggesting that AKAP4 can have a potential to be 
considered as a prognostic biomarker to predict metastasis 
in CRC patients. Therefore AKAP4 may have a potential 
AKAP4 Expression 
percentage
Clinical Factor Number of cases - + P-
value
Gender Male (n=27) 33 67
Female (n=34) 50 50 0.207
Age (years) >50 (n=39) 62 38
≤50 (n=21) 48 52 0.414
T category Tx (n=2 ) 50 50
T1 (n=5) 60 40
T2 (n=14) 79 21 0.301
T3 (n=30) 43 57
T4 (n=9) 56 44
T category (B) TX & T1 & T2 
(n= 21)
73 27
T3 & T4 (n=39) 45 55 0.059
M category M0 (n=51) 63 37
M1 (n=11) 27 73 0.045*
N category (A) N0 (n=31) 61 39
N1 (n=22) 50 50 0.715
N2 (n=9) 56 44
N category (B) N0 (30) 63 37
N1 & N2 (31) 52 48 0.44
Tumor Size(A) 
(centimeters)
1.5-3 (n=22) 55 45
3.1-5.5 (n=19) 53 47 0.889
5.6-12 (n=20) 60 40
Relapse - (n=43) 61 39
+(n=13) 38 62 0.21
Stage Stage 0 (n=6) 50 50
Stage 1 (n=14) 79 21
Stage 2 (n=19) 37 63 0.192
Stage 3 (n=16) 62 38
Stage 4 (n=7) 57 43
Table 3. The Relation between the Percentages of the 
Positive Samples for AKAP4 Gene Expression and 
Clinicopathological Data at Diagnosis
p* < 0.05 significance association between gene expression and 
clinical risk factors; T category, The rate of growth and progression of 
tumors in the intestinal wall layers based on the pathological division. 
M, Metastasis to other organs (M0, non metastati; M, metastatic). 
N, Lymph node involvement (N0, no involvement); Tumor Size, 
The length of tumors in centimeters; Relapse, Tumor Recurrence (+: 
Recurrence, -: no Recurrence); Stage, Stage of cancer according to 
TNM classification System and pathological data.




Clinical Factor Number of cases 
at diagnosis
Number of cases 
after follow up
- + P-value + - P-value
Metastasis to liver M0 (n=51) M0 (n=48) 63 37 31 69
M1 (n=11) M1 (n=14) 27 73 0.045* 45 55 0.485
Relapse - (n=43) - (n=42) 61 39 46 54
+(n=13) +(n=14) 38 62 0.21 33 67 0.948
Table 4. The Coexpression of AKAP4 and SPAG9 in CRC Patients after Follow up
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role in disease progression and tumorigenesis.
Wang et al., (2013) demonstrated overexpression 
of SPAG9 in NSCLC and its direct correlation with 
tumor differentiation, pTNM stage, nodal status and 
poor survival. Moreover, their data showed for the 
first time that SPAG9 could promote lung cancer cell 
invasion, possibly by enhancing JNK-mediated MMP9 
transcriptional activation. Given these findings, SPAG9 
might be a potential therapeutic target in the treatment 
of lung cancer, and future studies may be warranted to 
investigate these possibilities. Sinha et al., (2013) detected 
SPAG9 mRNA and protein expression in all breast 
cancer cells. Their data indicated that down regulation of 
SPAG9 reduces growth and invasive potential of triple-
negative breast cancer cells, suggesting that SPAG9 
may be a potential target for therapeutic use. Yu et al., 
(2011) showed that SPAG9 antibodies were detected in 
approximately 72% of patients with endometrial cancer 
but not in healthy controls. A significant difference 
has been found among pathological types and degrees 
(P < 0.05), and it was also found to be expressed in 
transferred lymph nodes. It may serve as a new type of 
endometrial cancer markers for early detection, diagnosis 
and treatment (Yu et al., 2012). Xie et al., (2014) analyzed 
SPAG9 expression in human HCC (Hepatocellular 
carcinoma) tissues by immunohistochemistry and found 
that SPAG9 overexpression is correlated with tumor 
stage (p<0.001), tumor multiplicity (p=0.019), tumor 
size (p=0.034), AFP levels (p=0.006), and tumor relapse 
(p=0.0017). Furthermore, they demonstrated that SPAG9 
overexpression is correlated with poor overall survival 
(p<0.001) and relapse-free survival (p=0.002) in HCC. 
Yi et al., (2013) showed that overexpression of SPAG9 
correlated with tumor grade (p<0.001). Li et al., (2014) 
using Immunohistochemistry showed that SPAG9 was 
overexpressed in 36.5 % of prostate cancer specimens. 
There was a significant association between SPAG9 
overexpression and tumor stage (p=0.0020) and Gleason 
score (p=0.0377). Garg et al., (2009) suggested that 
SPAG9 mRNA and protein expression was detected in 
78% of the thyroid cancer patients but not multiple goiters 
and follicular adenoma disease patients. They concluded 
SPAG9 expression may play a role in cellular growth 
and thyroid carcinogenesis (Garg et al., 2009b). RT-PCR, 
in situ RNA hybridization, and immunohistochemical 
analyses revealed that SPAG9 expression was significantly 
associated with tumor grades in 82% of early stage cervical 
cancer specimens (Garg et al., 2009a). Kanojia et al., 
(2011) RT-PCR analysis showed that 58 of 78 (74%) 
CRC patients expressed SPAG9 mRNA. They concluded 
testing for SPAG9 may be useful for early detection of EC 
(Esophageal cancer) in asymptomatic high-risk women. 
Garg et al., (2008) investigated the clinical relevance of 
SPAG9 in RCC (Renal cell carcinoma) patients. RT-PCR 
analysis showed expression of SPAG9 transcript in RCC 
tissues and RCC cell lines. In situ RNA hybridization and 
immunohistochemistry analyses confirmed the expression 
of SPAG9 in 88% of cancer patients, suggesting that 
SPAG9 participates in renal cancer. SPAG9 mRNA 
and protein expression was detected in 90% of EOC 
(Epithelial Ovarian Cancer) tissues and in all three human 
ovarian cancer cell lines by Garg et al., (2007). In the 
present study, the SPAG9 expression was investigated 
in various histotypes of CRC by RT-PCR technique. We 
demonstrated that majority of colorectal cancer patients 
(66%) showed SPAG9 expression irrespective of clinical 
stages and histological grades of tumor suggesting that 
SPAG9 may have a potential role in disease progression 
and tumorigenesis. 
Relationship between expression of AKAP4, SPAG9 and 
CTAG1B genes with clinical risk factors in CRC patients
Liver metastasis
In this study, the expression of AKAP4 gene in 
Iranian colorectal cancer patients was investigated 
and it was observed that the expression of this gene in 
CRC patients with metastasis of tumor to the liver was 
significantly different from those with primary tumor of 
CRC. Therefore, there is a significant relationship between 
the expression of this gene and metastasis in the liver in 
patients with colorectal cancer (P-value = 0. 045). In this 
study, the expression of SPAG9 gene for the first time 
in Iranian colorectal cancer samples was studied. The 
qualitative expression of this gene was not significantly 
different between people with malignant tumor CRC and 
those with primary tumor of this cancer (P-value = 458).
Metastasis to lymph nodes
Spreading metastases from lymph nodes to other 
locations is considered as a general feature of carcinoma, 
and the spread of lymphoid tumor cells occurs fairly early; 
this process is common in CRC patients. In this study, 
the qualitative expression of AKAP4 and SPAG9 genes 
was not significantly associated with metastasis to lymph 
nodes (state B) and with the number of nodes involved in 
metastasis (state A) (P value> 0.05). These data indicate 
that the expression of these genes in individuals with 
a higher number of metastatic lymph nodes (N2) is no 
different from those with less metastatic lymph nodes 
(N1).
Tumor growth rate in the intestinal wall (T factor)
The qualitative expression of AKAP4 and SPAG9 genes 
did not show any significant relationship with tumor 
growth in the intestinal wall (T) (P> 0.05). One of the ways 
in which liver metastases in CRC patients is tumor growth 
in the intestinal wall and passing through it, and invasion 
of nearby organs such as the liver around the intestine. 
Although, according to the obtained data, the expression 
of AKAP4 gene is associated with liver metastasis, but 
does not have a significant relationship with the T factor. 
Perhaps this is due to the fact that the T factor has four 
grades and just T4 passes through the intestinal wall and 
metastases to the surrounding organs. The number of T4 
patients enrolled in this study is low and is not statistically 
comparable. On the other hand, although the expression of 
genes associated with liver metastasis is not accompanied 
by tumor growth in the intestinal wall, this finding suggests 
that the metastatic potential has been created from the very 
early stages of the tumor, and the growth of the tumor in 
the layers of intestinal wall is an independent factor of the 
expression of genes. In other words, the tumor growth and 
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expression of genes should be considered simultaneously.
Tumor size
In this study, the relationship between the expression 
of AKAP4 and SPAG9 genes and the size of the tumor 
(tumor length) in CRC patients is reported. The qualitative 
expression of these genes was not significantly correlated 
with tumor size in three groups (1.5-3), (3.1-5.5) and 
(5.6-12) cm (P> 0.05). These findings are not unexpected 
due to the role of AKAP4 and SPAG9 gene products as 
scaffold proteins.
Age and sex
The qualitative expression of the studied genes in this 
study was completely independent of the sex and age 
of the patients and there was no significant relationship 
between them (p <0.05). These findings indicate that age 
and gender factors do not play a role in expressing of these 
genes, and this is the tumor phenotype that determines the 
expression of genes.
Cancer stage
In this study, there was no significant correlation 
between qualitative expression of the genes and cancer 
stage (p >0.05).
Cancer recurrence
In this study, there was no significant correlation 
between qualitative expression of the genes with cancer 
recurrence (p >0.05). Thus, in patients whose cancer 
has recurred, there has not been a steady pattern in the 
expression of genes.
In conclusion, according to this fact that AKAP4 and 
SPAG9 gene only expressed in normal testis and tumoral 
CRC tissues but not in normal colon tissues they can be 
used as a diagnostic biomarker for colorectal cancer.
From all clinicopathological factors investigated in 
this study, AKAP4 gene expression was significantly 
correlated with liver metastasis. Thus AKAP4 gene 
expression may be used as a risk factor and alarm for 
metastasis (potential prognostic biomarker).
In this study we observed NYESO-1 gene expression 
in none of CRC patients. So this gene expression has no 
role in tumorigenesis of CRC.
Since the useful features of a biomarker should be such 
that its measurement method be simple, fast, affordable 
and inexpensive, RT-PCR technique employed in this 
study has this features and could be applied in CRC 
specimens in any genetic laboratory.  
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